while this position could be understood, if not agreed with, when there was no data, it is untenable now that there is a growing body of data against it.
trial data of the new vaccines did not adequately represent these ultra high risk groups for vaccine efficacy. real world data showed a great reduction in nursing home and other deaths with vaccination and to some degree after the first dose. much of this data came before the more contagious and dangerous b 1.1.7 strain, first detected in the united kingdom, greatly dominated infections in many countries.
studies from germany and england, and now b.c. have shown highly concerning lack of antibody production after a first dose in many elderly, immune compromised and cancer patients which can be greatly boosted by a timely second dose. in the uk study of cancer patients, 95 per cent developed adequate antibody response with two appropriately timed pfizer doses but only 43 per cent if the second dose was delayed.
further evidence of the need for an early second shot for older people comes from a recent danish study published in the lancet that showed increased risk of reinfection after getting covid-19 based on age. this is evidence of declining protection from the antibody response to first infection, similar to the declining benefit from vaccination without a booster. younger people had an 80 per cent freedom from reinfection compared to only 47 per cent for those over 65.